Evasion of apoptosis is one of the crucial acquired capabilities used by cancer cells to fend
off anticancer therapies. Inhibitor of apoptosis (IAP) proteins exert a range of biological …

It is well accepted that the ability of cancer cells to circumvent the cell death program that
untransformed cells are subject to helps promote tumor growth. Strategies designed to …

The X-linked inhibitor of apoptosis protein (XIAP) is a potent cellular inhibitor of apoptosis.
Designing small-molecule inhibitors that target the BIR3 domain of XIAP, where …

DNA damage, chromosomal abnormalities, oncogene activation, viral infection, substrate
detachment and hypoxia can all trigger apoptosis in normal cells. However, cancer cells …

The inhibitor of apoptosis proteins (IAPs) are a family of antiapoptotic proteins that bind and
inhibit caspases 3, 7, and/or 9, but not caspase 8. Growing evidence also indicates that IAPs …

Apoptosis has been accepted as a fundamental component in the pathogenesis of cancer,
in addition to other human diseases including neurodegeneration, coronary disease and …

The X-linked inhibitor of apoptosis (XIAP) is a promising new molecular target for the design
of novel anticancer drugs aiming at overcoming apoptosis-resistance of cancer cells to …

Inhibitor of apoptosis (IAP) proteins are overexpressed in many cancers and have been
implicated in tumor growth, pathogenesis, and resistance to chemo-or radiotherapy. On the …

Cancer cells are characterized by self-sufficiency in the absence of growth signals, their
ability to evade apoptosis, resistance to anti-growth signals, sustained angiogenesis …

Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently
undergoing clinical development for the treatment of cancer. Using a range of assays that …